|
| |
BioMarin PharmaceuticalBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, focusing on product candidates that:
* Address currently unmet medical needs
* Suggest a clear-cut development profile
* Provide an opportunity to be first-to-market
The company's product portfolio is comprised of three approved products and multiple investigational product candidates. [link to Preclinical product chart: 3.1] FDA-approved products include KuvanŽ (sapropterin dihydrochloride) tablets for PKU, an oral small molecule therapeutic developed in partnership with Merck Serono; NaglazymeŽ (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; and AldurazymeŽ (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation. Investigational product candidates include PEG-PAL for the treatment of phenylketonuria (PKU), and 6R-BH4, currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease.
| Contact Details: |
| 105 Digital Drive |
| Novato |
| |
| 94949 |
| United States of America |
| Tel: | 415 884 6700 |
| Fax: | 415 832 7889 |
| Email: | jprice@biomarinpharm.com |
| WWW: | www.bmrn.com/
|
| |
Recent Publications by BioMarin Pharmaceutical: |  |
Development of a functional bioassay for arylsulfatase B using the natural substrates of the enzyme.
A functional bioassay has been developed for measuring the intracellular... | 18th August, 2009
| BioMarin Pharmaceutical
| Anal Biochem. 2009 Dec 15;395(2):144-50. Epub 2009 Aug 13.
DOI Direct Link |
Comparison of neutralizing antibody assays for receptor binding and enzyme activity of the enzyme replacement therapeutic Naglazyme (galsulfase).
Most patients receiving Naglazyme (galsulfase, rhASB) enzyme replacement... | 17th December, 2008
| BioAnalytical Sciences, BioMarin Pharmaceutical Inc., 105 Digital Drive,
| AAPS J. 2008 Sep;10(3):439-49. Epub 2008 Aug 16.
DOI Direct Link |
Development, validation, and clinical implementation of an assay to measure total antibody response to naglazyme (galsulfase).
Naglazyme (galsulfase, rhASB) was developed as enzyme replacement therapy... | 4th November, 2008
| BioAnalytical Sciences, BioMarin Pharmaceutical Inc., 105 Digital Drive,
| AAPS J. 2008 Jun;10(2):363-72. Epub 2008 Jul 8.
DOI Direct Link |
Dye ligand chromatography.
Dye affinity chromatography is a purification technique offering unique... | 17th October, 2008
| Process Sciences Department, BioMarin Pharmaceutical Inc, Novato, CA, USA.
| Methods Mol Biol. 2008;421:61-9.
|
Immunoaffinity chromatography.
Immunonaffinity chromatography is a powerful technique for rapid... | 17th October, 2008
| Process Sciences Department, BioMarin Pharmaceutical Inc, Novato, CA, USA.
| Methods Mol Biol. 2008;421:53-60.
|
→View more BioMarin Pharmaceutical research publications. |
Press Releases on BioMarin Pharmaceutical:
|
 |
| Particles Detected in Vials from Genzyme's Plant Not Expected to Impact Aldurazyme or Naglazyme |
13th November, 2009 |
BioMarin Pharmaceutical Inc. |
NOVATO, Calif., Nov. 13 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Genzyme notified the company that, in rare circumstances, it has detected foreign
|
| United States Patent Office Issues Patent Covering the Approved Administration of Kuvan With Food |
5th November, 2009 |
BioMarin Pharmaceutical Inc. |
NOVATO, Calif., Nov. 5 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the United States Patent and Trademark Office has issued a patent covering the
|
| BioMarin to Present at the Credit Suisse Healthcare Conference |
4th November, 2009 |
BioMarin Pharmaceutical Inc. |
NOVATO, Calif., Nov. 4 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company
|
| BioMarin Announces Third Quarter 2009 Financial Results |
28th October, 2009 |
BioMarin Pharmaceutical Inc. |
Financial Highlights ($ in millions, except per share data)
Item Q3 2009 Q3 2008 Comparison
Total BioMarin
Revenue $80.8
|
| BioMarin to Present at the Oppenheimer Healthcare Conference |
27th October, 2009 |
BioMarin Pharmaceutical Inc. |
NOVATO, Calif., Oct. 27 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Hank Fuchs, M.D., Chief Medical Officer of BioMarin, will present a company update at
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 677 times since April 2007, the link to the organisation's website has been followed 85 times Recent Search Terms used to find this page: biomarin ppd | biomarin bienaime email | biomarin bienaime email | department of bioanalytical sciences biomarin | biomarin patents N-acetylgalactosamine-4-sulfatase 2 | biomarin email | biomarin email | bioassayfor naglazyme | purification of naglazyme | purification of Naglazyme Galsulfase | . Search for more companies in Novato Search for more companies in This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for BioMarin Pharmaceutical |
